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Interphase cytogenetics was used to investigate the clonal ori­
gin of bone marrow (BM) cells, peripheral blood (PB) cells, and 
in vitro cultured progenitor cells of five patients with acute 
myeloid leukemia (AML) and myelodysplasia (MDS). A new in 
situ hybridization (ISH) technique was used to examine the ori­
gin of the progenitor cells. Two patients with, respectively, tri­
somy 8 and polyploidy as ISH marker were studied both at pre­
sentation and during remission. At presentation, the in vitro 
cultured clusters of both cases appeared diploid. Therefore, 
despite the abnormal growth patterns, the cultured progenitors 
could have been residual normal cells. Alternatively, they could 
have originated from a preleukemic clone with a normal kary­
otype. In both cases abnormal BM and/or PB cells (less than 
6%) were detected with ISH during remission, indicating par­
tially or completely clonal remissions in these patients. Both 
patients have relapsed. One patient with trisomy 10 as ISH 
marker was analyzed during myelodysplastic phase and after 
progression to AML. On both occasions, abnormally appearing 
clusters were cultured. However, only part of the clusters car­
ried trisomy 10. The presence of a subclone characterized by 
trisomy 10 and an abnormally growing (pre)leukemic clone 
without trisomy 10 may explain this observation. Monosomy 1 
and 17 were respectively used as ISH markers in two other AML 
patients. All in vitro cultured clusters carried the numerical 
abnormality. Long-term liquid cultures of these leukemias were 
performed for 10-20 days. In both cases, no residual normal 
clonogenic cells could be detected. Therefore, the selective 
growth advantage of normal progenitor cells in long-term mar­
row cultures could not be demonstrated in these two patients 
with leukemia. This paper illustrates the usefulness of ISH to 
study the biology of AML at the clonogenic level during preleu­
kemic phase, active disease, remission, and under in vitro cul­
ture conditions. It is a sensitive technique which allows indivi­
dual analysis of large numbers of small aggregates and single 
cells in culture.
Keywords: acute myeloid leukemia; interphase cytogenetics; myel­
odysplasia; progenitor cells
Introduction
Acute myeloid leukemia (AML) may be considered as a clonal 
expansion of one single transformed cell.1,2 The origin of the 
leukemic clone may be either a multipotential hematopoietic 
stem cell (HSC) or a cell restricted to the granulocyte-mono- 
cyte pathway.1'2 In myelodysplastic syndrome (MDS), the 
abnormal clone is assumed to arise at stem cell level.3 In the 
majority of AML/MD5 cases, progenitor cells can be cultured 
in vitro.4' 6 The origin of these clonogenic cells may be diffi­
cult to assess, since colonies derived from (pre)leukemic pro­
genitors are not always morphologically distinguishable from 
those derived from normal progenitors (7).
Several techniques have been developed to determine the 
clonal origin of hematopoietic ceils. In heterozygous females,
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the X-chromosome-l inked enzyme glucose-6-phosphate 
dehydrogenase (G6PD) or restriction fragment length poly­
morphisms (RFLP) or other X-chromosomai enzymes can be 
used as a genetic marker.1,2,8 Karyotyping and surface marker 
expression analysis offer alternative approaches.2,9,10 Progeni­
tors of AML patients at presentation are usually derived from 
the malignant clone. Occasionally, the myeloid colonies 
appeared to originate from normal stem cells.7 During 
remission, in most patients restoration of nonclonal hemato- 
poiesis and repopulation of the marrow by normal stem cells 
has been observed. Clonal remissions have also been 
observed,3,10,11
The results obtained with long-term bone marrow culture 
(LTBMC) of BM cells from AML patients additionally support 
the presence of residual normal stem cells in leukemic pa­
tients during active disease. In most cases, leukemic colonies 
and clusters were no longer detectable after 1 to 4 weeks of 
culture.12"14 The few reports about progenitors in MDS suggest 
the existence of a transformed stem cell either with or without 
an abnormal karyotype.5,15
Recently, we described a method to determine chromoso­
mal aberrations by ISH in myeloid progenitor cells cultured 
in agar.10,17 The present study investigates the genetic clona- 
lity of myeloid progenitor cells and nucleated cells in five pati­
ents with AML and MDS at different stages of their disease.
Patients and methods
Patient selection
Patients with de novo AML or AML after a myelodysplastic 
phase characterized by a numerical chromosomal aberration 
were selected for this study. AML and MDS were diagnosed 
according to the French-American-British classification,10'19 
Patient 1 was assessed at diagnosis and in complete remission. 
He relapsed 6 months after the last analysis (May 1992). Pa­
tient 2 presented with a leukemoid reaction during an exacer­
bation of her ulcerative colitis. This was followed by a 'spon­
taneous' remission of 5 months without any antileukemic 
therapy. Patient 3 was investigated during the myelodysplastic 
phase and after leukemic transformation. Patients 4 and 5 
were studied at presentation of AML. The relevant clinical and 
hematological data are shown in Table 1.
Cell collection, cryopreservation and thawing
Bone marrow cells were collected, cryopreserved in liquid 
nitrogen and thawed as described in detail elsewhere.20 For 
ISH, cells were fixed in 70% ethanol (-20 ° C) and stored at
— 30° C until further use.
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Table 1 Clinical data
Case Date D/sease Age Sex WBC Hb Platelets Blood BM FAB
no. status (years) (10°/i) (mmoi/l) (m o % blasts % blasts type
1 2/88 AML 52 M 10.5 6.4 26 3 85 M4
5/91 CR 8.6 7,5 173 0 0
11/91 CR 5.4 6.9 155 1 NA
2 4/87 ïeukemoid
reaction’
34 F 43.6 7.7 236 2 36
9/87 AML 46.9 7.4 23 42 80 M4
2/88 CR 6.7 7.8 140 0 2
3 12/91 MDS 54 M 7.3 7.1 30 2 6 RAEB
5/92 AML 24.7 5.7 12 33 M2
4 5/89 AML 60 M 21.6 5.7 16 27 28 M6
5 2/89 AML 58 M 8.6 5.6 29 73 75 M2
M, male; F, female; WBC, white blood cells; Hb, hemoglobin; BM, bone marrow; FAB, French-American-British classification;22’23 NA, 
not available
Human recombinant growth factors
Human recombinant interleukin 3 (IL-3) and human recombi­
nant granulocyte-monocyte colony-stimulating factor (GM- 
CSF) were kindly donated by Sandoz (Uden, The 
Netherlands). Human recombinant granulocyte colony-stimu­
lating factor (G-CSF) was a kind gift from Behring (Marburg, 
Germany). Final concentrations of 40 ng/ml, 20 ng/ml, and 
5 ng/ml, respectively, were used and resulted in plateau stimu­
lation.
Clonogenic assay (CFU-C)
Cells were cultured in Iscove's medium, supplemented with 
20% FCS, 50 lU/ml penicillin, 50 ¿¿g/ml streptomycin, and 
0.3% bacto-agar (Difco, Detroit, Ml, USA). The cells were 
stimulated with the combination of IL-3, GM-CSF and G-CSF. 
Duplicates were cultured in 35X10  mm culture dishes 
(Costar, Cambridge, MA, USA) at 37° C in a fully humidified 
atmosphere containing 5% C 02. In order to render the cells 
better accessible for the DNA probes, a reduced volume of 
0.85 ml per dish was plated.16 After 7 days, the total number 
of clusters (5-40 cells) and colonies (>40 cells) was counted. 
A pattern of small (maximum size, 20 cells) or large 
(maximum size, 40 cells) cluster formation was usually 
observed. After counting, the agar cultures were dried by a 
method based on a technique described by Baines.21 The cul­
tures were shaken into glucose-phosphate buffer and divided 
into quarters. Each quarter was spun down on a 76 X  26 mm 
poly-L-lysine (Sigma, St Louis, MO, USA; MW; 150 000- 
300 000) coated glass slide by cytocentrifugation. Samples 
were processed for ISH or stained with hematoxylin solution 
(Merck, Darmstadt, Germany) to evaluate morphology.
Liquid culture
Cells were suspended in Iscove's medium supplemented with 
20% FCS, 50 lU/ml penicillin, 50 jug/ml streptomycin and a 
combination of IL-3, GM-CSF and G-CSF. The liquid cultures 
were maintained in an incubator (37° C, 5% C 0 2 and fully 
humidified atmosphere) for a period of up to 20 days. At re­
gular intervals, part of the ceils were collected, washed and 
used for clonogenic assay and ISH.
Karyotyping
Metaphase spreads were obtained from BM or PB cells after 
culturing in RPMl 1640 (Flow Laboratories, McLean, VA, 
USA) for 1 or 24 h. Colcemid was present during the last hour 
of the culture. Before fixation in methanol ; glacial acetic acid 
(3:1), the cells were exposed to a hypotonic solution 
(0.075 m KCI) for 15 min. Slides were prepared according to 
routine cytogenetic procedures. Karyotyping was performed 
using the GTG technique.
In situ hybridization
ISH was performed on cell suspensions and dried agar cul­
tures as described before.16 For good penetration of the DNA 
probes and antibodies, a proteolytic digestion step with pepsin 
(P7000; Sigma) was performed at a concentration of 
100 ¿¿g/ml in 0.01 m HCI for 20 min at 37° C. The nuclei were 
post-fixed in 4%  formaldehyde in PBS for 20 min at 4° C. Ten 
microliters of the hybridization mixture (60% formamide, 
0.6 M NaCI 60 mM sodium citrate (2 X  SSC), 10% dextran sul­
phate and a probe concentration of 1 ng//J) was applied 
under a coverslip. Denaturation of target DNA and probe was 
carried out simultaneously at 70° C for 2.5 min in a moist 
chamber and hybridization was performed for 2-16 h at 
37° C. Subsequently, the hybridized probes were detected by 
horseradish peroxidase (HRP)-conjugated avidin (Dakopatts, 
Glostrup, Denmark). Finally, the DNA probe was visualized 
with 0.5 mg/m! 3,3-diaminobenzidin tetrahydrochloride 
(DAB; Sigma), 0.65% imidazole (Merck), 0.015% H20 2 
(Merck), at pH 7.8 in PBS. As controls, the samples were 
hybridized with a chromosome-specific DNA probe for which 
no chromosomal aberration was detected. In these controls 
the cells from suspension preparations demonstrated one ISH 
signal for a target chromosome in 5-10% of the cells, and 
three ISH signals in <2% of the cells. Of these suspension 
preparations, 200 nuclei per slide were counted. The agar 
preparations were evaluated by counting 100 single cells and 
approximately 50 aggregates. In these controls, at least 90% 
of the cells contained ISH signals. The percentages of cells 
containing the euploid number of ISH signals for the control 
DNA probe-targets varied between 85 and 90%.16,17
Results Case 2
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Case 1
Presentation of AML: At presentation, 12 of 13 analyzed 
BM cell metaphases showed trisomy 8 by karyotyping (Table 
2). With ISH, trisomy 8 was found in 71% of the BM cells. 
A leukemic growth pattern was observed with small clusters 
consisting of 5-25 immature myeloid cells. After hybridization 
with the probe for chromosome 8, disomy was found in all 
analyzed clusters, whereas 14% of the single cells in the semi­
solid culture had trisomy 8.
Complete remission: In May 1991, karyotyping revealed 
only normal BM cells, whereas no metaphases could be 
detected in the PB. However, with ISH, 6% of the BM cells 
showed trisomy 8. Both BM and PB exhibited a normal in 
vitro growth pattern. The colonies appeared morphologically 
normal and were diploid when analyzed with the probe for 
chromosome 8. By contrast, in the BM culture, respectively 
19 and 4% of the single cells in agar had trisomy and tetra- 
somy for chromosome 8, whereas the single cells of the PB 
cultures showed trisomy and tetrasomy 8 in 12 and 2% 
respectively.
In November 1991 only PB was analyzed. No metaphases 
were detected. ISH on cell suspension was not performed. A 
normal growth pattern was observed demonstrating disomy 8 
in all aggregates, while part of the single cells in culture had 
trisomy 8 (7%).
At leukemic presentation, all investigated BM metaphases 
appeared to be polyploid, containing about 96 chromosomes 
(Table 2). For ISH analysis, we applied the probe for chromo­
some 1 in this particular case.
'Leukemoid r e a c t i o n During 'leukemoid reaction', a nor­
mal karyotype was found in nine bone marrow metaphases 
(Table 2). In contrast, ISH revealed that 4%  of the BM cells 
contained three or four ISH signals with the chromosome 1 
probe. The number of colonies in the semi-solid culture was 
depressed. Morphology and size of the colonies appeared nor­
mal. All analyzed colonies were disomic, whereas 8% of the 
single cells in agar contained three or four ISH signals.
Presentation: During overt leukemia, when all analyzed 
BM metaphases were polyploid, tri- or tetrasomy 1 was found 
by ISH in 62% of the BM cells. Only very few colonies and 
clusters could be cultured in agar. They appeared to have nor­
mal morphology and size and were disomic when hybridized 
with the probe for chromosome 1. Sixty-six percent of the sin­
gle cells in those cultures were tri- or tetrasomic.
Complete remission: In February 1988, both normal and 
polyploid cells were detected by cytogenetic analysis. ISH 
revealed tri- or tetrasomy 1 in 5%  of the BM cells. Normal 
colony numbers were observed. Their morphology and size 
also appeared normal. All analyzed colonies were disomic,
Table 2 Bone marrow and blood (case nos 1, 2 and 3)
Case
no,
Date Disease
status
Cell
sample
1 2/88 AML BM
5/91 CR BM
5/91 CR PB
11/91 CR PB
2 4/87 'leukemoid
reaction'
BM
9/87 AML BM
2/88 CR BM
3 12/91 MDS BM
Suspension Semi-sol id
Karyotype ISH (%) ISH ISH
colonies/clusters single cells (% )
CFU-CC
colonies/clusters
5/92 AML
PB
BM
46.XY/47.XY,+8 
(n = 1/12)a (92%) 
46,XY (n = 32)
no metaphases 
found
no metaphases 
found
46,XX (n = 9) 
polyploid (about
96 chromosomes, 
n = 6)
(100%)
46,XX/polyploid 
(n = 14/2) (13%) 
461XY/47,XY, + 10 
(n = 24/8) (25%) 
NA
no metaphases 
found
trisomy 8 (71) 
trisomy 8 (6)
NA
NA
trisomy 1 (1) 
tetrasomy 1 (3) 
trisomy 1 (18) 
tetrasomy 1 (44) 
(62)
trisomy 1 (2) 
tetrasomy 1 (3) 
trisomy 10 (26)
trisomy 10 (14)
trisomy 10 (16)
disomy 8 (n = 17)b trisomy 8(14)
disomy 8 (n = 21) 
disomy 8 n - 18) 
disomy 9 (n = 18) 
disomy 1 (n = 17) 
disomy 1 (n = 38)
trisomy 8(19) 
tetrasomy 8 (4) 
trisomy 8 (12) 
tetrasomy 9 (2) 
trisomy 8 (7)
trisomy 1 (2) 
tetrasomy 1 (6) 
trisomy 1 (16) 
tetrasomy 1 (50)
disomy 1 (n - 39)
disomy
trisomy
disomy
trisomy
disomy
trisomy
10 (n 
10 (n 
10 (n 
10 (n 
10 (n 
10 (n
6)
14)
18)
17)
23)
7)
trisomy (1) 
tetrasomy 1 (1) 
trisomy 10 (35)
trisomy 10 (37)
trisomy 10 (8)
ISH, in situ hybridization; BM, bone marrow; PB, peripheral blood; OR, complete remission; NA, not analyzed.
aNumber of mitosis.
bNumber of analyzed aggregates.
cNumber of CFU-C per 2 x 105 NC (BM) or 8 x 105 NC (PB)
0/89
99/34
33/20
42/20
12/21
4/5
140/14
1/116
1/43
18/2160
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whereas 2% of the single cells in the semi-solid culture were 
tri- or tetrasomie.
Case 3
MDS: Karyotyping of the BM revealed that eight of 32 
analyzed metaphases had trisomy 10 (Table 2). With ISH, 
26% of the BM cells had trisomy 10. in the PB cells, on which 
no karyotyping was performed, 14% of the cells showed tri­
somy 10 by ISH. Both BM and PB cells were growing as clus­
ters consisting of 5-35 immature cells. Although morphologi­
cally not distinguishable, both clusters with and without 
trisomy 10 were observed by ISH in these cultures. The single 
cells in the BM and PB cultures demonstrated a trisomy for 
chromosome 10 in 35 and 37%, respectively.
Presentation; At leukemic presentation, no BM meta­
phases were detected. By ISH, 16% of the BM cells had tri­
somy 10. The clusters appeared morphologically identical to 
the clusters cultured during MDS phase. Trisomy 10 was 
found in seven of 30 clusters (Figure 1), whereas 8% of the 
single cells in culture showed trisomy 10.
In the following two cases bone marrow was cultured in 
liquid in the presence of 1L-3, GM-CSF and G-CSF for up to 20 
days to investigate whether residual normal progenitors had a 
growth advantage compared to the leukemic clone.
cantly influence the number of abnormal cells and clusters. 
Ninety-one percent of the cells in suspension showed mono­
somy 1. Again, only immature appearing small clusters could 
be cultured, and all showed monosomy for chromosome 1. 
The single cells in the semi-solid assay demonstrated a mono­
somy 1 in 91%.
Case 5
Presentation: Nine out of 10 metaphases showed multiple 
chromosomal aberrations (Table 3), In this case, monosomy
17 was chosen as ISH marker. Monosomy 17 was detected 
by ISH in 96% of the BM cells. The clusters consisted of 5- 
25 immature cells and all were monosomic for chromosome 
17. Moreover, monosomy 1 7 was found in 82% of the single 
cells in the semi-solid assay.
Liquid culture: The high plating efficiency allowed in 
liquid culturing of the leukemic cells for up to 20 days. Liquid 
culture cells and agar cultures (both single cells and clusters) 
were analyzed at regular intervals. During the whole period 
the proportion of abnormal cells in liquid remained essentially 
the same (95-99%), At any time, only aggregates with mono­
somy 17 were detected by ISH (see Figure 1a).
Discussion
Case 4
Presentation: At leukemic presentation, karyotyping of BM 
cells revealed multiple abnormalities In almost all metaphases 
(Table 3). The probe for chromosome 1 was selected as a 
marker for ISH. Monosomy 1 was found in 71% of the BM 
cells. The in vitro growth pattern consisted of small clusters 
(5-20 cells) consisting of immature cells. All analyzed clusters 
and 88% of the single cells showed monosomy 1.
Liquid culture: Liquid culture for 10 days did not signifi-
• •* e- *4':. i . •
:* v; iX'v :
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Figure 1 In situ hybridization examples of in vitro cultured pro­
genitor cells from patients with AML. (a) A small cluster of case no. 
5, cultured after 20-day liquid culture, demonstrating one ISH signal 
for chromosome 17 per cell, (b) A small cluster of case no. 3 at presen­
tation, demonstrating three ISH signals per cell for chromosome 10
Five patients with de novo AML or AML after a myelodysplas- 
tic phase and abnormal clones characterized by numerical 
chromosomal abnormalities were the subject of this study. In 
all cases, the chromosomal aberrations observed by cyto­
genetic analyses could also be detected by ISH. The percen­
tage of abnormal cells was within the same range for both 
methods taking into account the following considerations. 
Conventional cytogenetic analysis examines fewer cells than 
ISH and this may result in a less accurate estimation of the 
real number of abnormal cells. Furthermore, conventional 
cytogenetic analysis is performed on dividing cells, which 
may lead to a selection for the abnormal subpopulation.f) 
Non-dividing interphase lymphocytes are included in the ISH 
analysis and cannot be analyzed by karyotyping. The lym­
phoid lineage is usually not a part of the abnormal clone and 
thus may account for the lower incidence of abnormal cells 
found with fSH,2 
The detection level of ISH analysis is more sensitive than 
conventional cytogenetic analysis, especially when trisomic 
or polyploic markers are used. The number of ISH signals is 
constant during the whole cell cycle, and in normal diploid 
cells the number of cells with four ISH signals is maximally 
1% .17 The sensitivity level of three ISH signals is at the level 
of 2-4%. ISH analysis detected 4% abnormal cells during the 
leukemoid' reaction of patient 2, while the nine metaphases 
revealed 46 normal chromosomes. This result may be 
regarded as of borderline significance, but is further supported 
by the presence of 8% trisomic or tetrasomic cells in the agar 
culture of this bone marrow. Remission marrow of patient 1 
contained only normal metaphases and 6% abnormal 
interphase cells as measured with ISH. This patient had per­
sisting abnormal cells in culture 6 months later and conse­
quently relapsed. Similar observations have been made in 
G6PD and RFLP studies.7'22
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Table 3 Bone marrow (case nos 4 and 5) 1171
Case Days of liquid 
no. culture
Suspension Semi-solid CFU-C*
colonies/clusters
Karyotype iSH (% ) ISH
colonies/clusters
ISH
single cells (% )
4 presentation
day 10 
presentation
day 5 
day 10 
day 14 
day 20
46,XY/44,XY,-1 ,-5,-7, 
-17,-20,-21,+marl, 
+mar2,+2xmar3 
(n = 2/34)a(94%)
NA
46lXY/43,X,3q,+8, + 10,
-5,-6-12,-13,-17-22,
+mar1-3 (n = 1/9)c(90%)
NA
NA
NA
NA
-Y
monosomy 1 (71) monosomy 1 (n = 35)b monosomy 1 (88)
monosomy 1 (91) 
monosomy 17 (96)
monosomy 17 (99) 
monosomy 17 (96) 
monosomy 17 (95) 
monosomy 17 (96)
monosomy 1 (n = 43) monosomy 1 (91) 
monosomy 17 (n = 42) monosomy 17 (82)
monosomy 17 (n 
monosomy 17 (n 
monosomy 17 (n 
monosomy 17 (n
38) NA 
55) NA 
27) NA
26) monosomy 17 (84)
0/380
0/180
0/5400
0/5100 
0/1100 0 
0/4500 
0/900
ISH, in situ hybridization; NA, not analyzed. 
aNumber of mitosis. 
bNumber of analyzed aggregates. 
cNumber of CFU-C per 2 X 105 NC
The ISH marker for abnormal cells was not detected in the 
cells of the clusters of patients 1 and 2. In both cases the bone 
marrow and blood cultures contained single cells with 
numerical abnormalities. The clusters could be the progeny 
of normal progenitor cells which exhibit an abnormal growth 
pattern due to influences of adjacent leukemic cells. In the 
majority of reported cases, myeloid progenitors are part of the 
leukemic clone at presentation. However, in a few patients, 
normal CFU-GM have been detected.7 It is important to 
realise that the ISH method enables the evaluation of small 
clusters and single cells in the cultures in situ while the 
methods based on G6PD isoenzymes or genetic analysts 
require micromanipulation of the colonies. The latter analyses 
can only be performed on larger colonies and this may have 
influenced the results. If the clusters in cases 1 and 2 did ori­
ginate from normal cells, then the in vitro growth pattern and 
morphology by itself are not sufficient to determine the origin 
of progenitor cells. An alternative explanation could be that 
these progenitor cells represent a part of the leukemic clone 
without the numerical aberration. This concept can be 
explained by a multistep leukemogenesis with a preleukemic 
stage; an early step causes clonal proliferation and a later step 
results in a chromosomal abnormality in descendants of 
these progenitors.8,11
In case 3 the progression from MDS to AML coufd be 
observed. The abnormal but identically appearing clusters 
could be distinguished in two subpopulations: one consisting 
of progenitors with and the other without trisomy 10 (Table 
2). No increase in the percentages of either BM cells or pro­
genitor cells with trisomy 10 was observed when the patient 
developed AML. Only the plating efficiency of cultured pro­
genitors increased. This observation matches the theory that 
MDS arises from a transformed progenitor cell and progresses 
from a preleukemic state to overt leukemia by successive gen­
etic changes.3'15 In that case, all cultured clusters belonged to 
a (pre)leukemic clone with abnormal growth characteristics, 
but only part of this clone obtained the chromosomal aber­
ration trisomy 10.
Patients 4 and 5 were selected because conventional cyto­
genetic analysis revealed a subpopulation of normal meta­
phases (Table 2). All cultured clusters from these patients con­
tained the numerical ISH abnormality. This was in agreement 
with the observed leukemic growth pattern and undifferen­
tiated appearance of the clusters, and confirmed the leukemic 
origin of these myeloid progenitors. Although in both cases 
part of the BM cell metaphase spreads and interphase nuclei 
appeared normal, no residual normal clonogenic cells could 
be detected after long-term culture in liquid. In the majority of 
reported cases, long-term marrow cultures provide a selective 
growth advantage for normal progenitor cells, but in some 
AML cases, as in patients 4 and 5, persistence of the leukemia 
has been observed.12' 14
Forty to 70% of the AMLs and 25-50% of the MDSs have 
numerical chromosomal abnormalities, indicating that a sub­
stantial number of patients with AML and MDS can be ana­
lyzed by ISH using centromere associated DNA probes.23,24 
Moreover, probes against fusion genes, such as bcr-abl gene, 
have become available.25 This may further increase the num­
ber of patients which can be studied by ISH techniques. By 
performing ISH on agar cultures, the cytological architecture 
remains intact. This enables individual analysis of large num­
bers of aggregates and single cells in the culture. Sample 
errors are avoided since removal of colonies is not necessary. 
In contrast to the conventional techniques, not only large 
colonies but also small clusters can be analyzed. Furthermore, 
it is less time consuming to investigate large numbers of aggre­
gates. Therefore, ISH may help to clarify the complex biology 
of MDS and AML both during 'full-blown' situation and clini­
cal remission. In addition, it can be applied to monitor in vitro 
culture systems. Additional studies are needed to explain the 
nature of small aggregates of some patients which have a nor­
mal diploid ISH signal.
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